Adaptive Biotechnologies Corporation (NASDAQ: ADPT from June 2019) offers immunoSEQ research service and kits used to answer research questions that inform current and future clinical trials, as well as to discover new prognostic and diagnostic signals. Also provided by the firm are clonoSEQ diagnostic tests - including immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. With a pipeline of clinical products and services used for the diagnosing, monitoring, and treatment of diseases, Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for neoantigen directed T cell therapies for the treatment of a range of cancers; and with Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. Serving the life sciences research, clinical diagnostics, and drug discovery customers, the company was formerly known as Adaptive TCR Corporation with the name change made in December 2011. Formed by researchers from the Fred Hutchinson Cancer Research Center, the firm tilizes high-throughput gene sequencing with computer infrastructure to allow scientists minutely to analyze T-cell receptors (TCR). This capability to perform DNA sequencing of T-cell receptors as a method of diagnosing and planning treatment for autoimmune diseases supports a breakthrough method of measuring a persons adaptive immunity through massive parallel sequencing of T cell receptors. By being able to sequence huge numbers of TCRs, researchers can learn their specific makeup for comparison and study - providing a path to further understand, diagnose, and identify treatments for a variety of cancer, autoimmune disorders, and infectious diseases - Adaptive TCR Corporation's T-cell receptor profiling allows scientists to study the adaptive immune system to an unprecedented depth via T-Cell Receptor (TCR) sequencing. Developing next generation sequencing assays that characterize the adaptive immune system, serves as a platform technology to the research community and the biopharmaceutical industry. Its flagship commercial product, immunoSEQ (http://www.immunoSEQ.com), uses a proprietary immune profiling assay to analyze T cells and B cells critical components of the adaptive immune systems defense against disease with unprecedented depth and specificity. Sequencing the variable region of these immune cells allows researchers to characterize the complete immune repertoire of a patient or group of patients in search of immunologic biomarkers. Fueled by discoveries from immunoSEQ, the company is currently developing a pipeline of clinical assays that are specific to cancer diagnosis and prognosis. With its first SBIR involvement soon after founding, the firm has continued follow-on Phase II funding on earlier initiated projects as recently as 2017
